

Jan Delabie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11071/publications.pdf>

Version: 2024-02-01

239
papers

34,444
citations

9756

73
h-index

3563

181
g-index

242
all docs

242
docs citations

242
times ranked

22286
citing authors

#	ARTICLE	IF	CITATIONS
1	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004, 103, 275-282.	0.6	3,574
2	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 1937-1947.	13.9	3,474
3	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	13.9	1,443
4	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010, 463, 88-92.	13.7	1,402
5	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. <i>New England Journal of Medicine</i> , 2004, 351, 2159-2169.	13.9	1,293
6	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011, 470, 115-119.	13.7	1,292
7	Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 362, 875-885.	13.9	1,141
8	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	4.2	1,002
9	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13520-13525.	3.3	868
10	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003, 3, 185-197.	7.7	848
11	Molecular Diagnosis of Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2006, 354, 2431-2442.	13.9	824
12	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	0.8	824
13	Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma. <i>Science</i> , 2008, 319, 1676-1679.	6.0	784
14	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	13.7	759
15	A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. <i>Clinical Cancer Research</i> , 2009, 15, 5494-5502.	3.2	577
16	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo "purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. <i>Blood</i> , 2008, 112, 2687-2693.	0.6	571
17	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	0.6	518
18	Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. <i>Journal of Clinical Oncology</i> , 2012, 30, 3093-3099.	0.8	490

#	ARTICLE	IF	CITATIONS
19	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.	0.6	435
20	Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, 200-207.	0.8	426
21	Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2010, 115, 1026-1036.	0.6	353
22	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005, 106, 3183-3190.	0.6	348
23	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , 2009, 94, 1555-1562.	1.7	345
24	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. <i>Blood</i> , 2005, 106, 4315-4321.	0.6	330
25	Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2011, 118, 148-155.	0.6	308
26	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> , 2004, 103, 4251-4258.	0.6	296
27	BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 961-968.	0.8	277
28	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	13.7	276
29	Cooperative Epigenetic Modulation by Cancer Amplicon Genes. <i>Cancer Cell</i> , 2010, 18, 590-605.	7.7	263
30	BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 165, 159-166.	1.9	262
31	Loss of signalling via $\text{G}\pm 13$ in germinal centre B-cell-derived lymphoma. <i>Nature</i> , 2014, 516, 254-258.	13.7	253
32	IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1686-1694.	2.1	251
33	Nordic <i>MCL</i> 2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <i>BEAM</i> or <i>BEAC</i> +Autologous stem cell support: still very long survival but late relapses do occur. <i>British Journal of Haematology</i> , 2012, 158, 355-362.	1.2	241
34	Point mutations and genomic deletions in <i>CCND1</i> create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007, 109, 4599-4606.	0.6	226
35	Follicular lymphomas with and without translocation <i>t</i> (14;18) differ in gene expression profiles and genetic alterations. <i>Blood</i> , 2009, 114, 826-834.	0.6	177
36	Structural profiles of <i>TP53</i> gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	0.6	173

#	ARTICLE	IF	CITATIONS
37	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (<sc>MCL</sc>): prolonged remissions without survival plateau. <i>British Journal of Haematology</i> , 2016, 175, 410-418.	1.2	170
38	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). <i>Blood</i> , 2010, 115, 1530-1533.	0.6	167
39	The Value of Anti-Pax-5 Immunostaining in Routinely Fixed and Paraffin-Embedded Sections. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1343-1350.	2.1	166
40	Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature. <i>Journal of Clinical Oncology</i> , 2007, 25, 1216-1222.	0.8	166
41	Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. <i>Blood</i> , 2003, 102, 3753-3758.	0.6	159
42	Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. <i>Blood</i> , 2013, 122, 3599-3606.	0.6	156
43	BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. <i>Clinical Cancer Research</i> , 2011, 17, 7785-7795.	3.2	152
44	High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. <i>Blood</i> , 2013, 121, 1367-1376.	0.6	147
45	In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. <i>Haematologica</i> , 2012, 97, 270-278.	1.7	146
46	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13447-13454.	3.3	143
47	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. <i>British Journal of Haematology</i> , 2007, 136, 286-293.	1.2	142
48	Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. <i>Haematologica</i> , 2014, 99, 497-504.	1.7	142
49	Marginal-Zone B Cells in the Human Lymph Node and Spleen Show Somatic Hypermutations and Display Clonal Expansion. <i>Blood</i> , 1999, 93, 226-234.	0.6	138
50	Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2352-2357.	3.3	138
51	Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. <i>Cancer Discovery</i> , 2014, 4, 480-493.	7.7	130
52	The Transcription Factor PU.1, Necessary for B-Cell Development Is Expressed in Lymphocyte Predominance, But Not Classical Hodgkin's Disease. <i>American Journal of Pathology</i> , 2001, 159, 1807-1814.	1.9	123
53	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. <i>Blood</i> , 2010, 116, 953-961.	0.6	122
54	Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. <i>British Journal of Haematology</i> , 2012, 156, 225-233.	1.2	116

#	ARTICLE	IF	CITATIONS
55	Translocation (11;14): A cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. <i>Journal of Pathology</i> , 1991, 163, 13-18.	2.1	113
56	Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4528.	0.8	113
57	SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2014, 166, 98-108.	1.2	110
58	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , 2014, 123, 1681-1690.	0.6	110
59	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , 2015, 125, 1137-1145.	0.6	110
60	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 4396-4405.	0.6	103
61	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	0.8	102
62	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001.	1.7	100
63	Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study. <i>BMC Bioinformatics</i> , 2002, 3, 36.	1.2	99
64	Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. <i>Blood</i> , 2012, 119, 4939-4948.	0.6	97
65	CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. <i>Cancer Research</i> , 2005, 65, 2199-2206.	0.4	93
66	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2016, 29, 494-507.	7.7	93
67	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014, 123, 2953-2959.	0.6	90
68	ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. <i>Haematologica</i> , 2010, 95, 509-513.	1.7	89
69	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	0.6	89
70	Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. <i>Blood</i> , 2005, 105, 2869-2876.	0.6	88
71	Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. <i>Haematologica</i> , 2015, 100, 238-245.	1.7	87
72	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. <i>Haematologica</i> , 2008, 93, 1327-1334.	1.7	80

#	ARTICLE	IF	CITATIONS
73	MicroRNA profiles of t(14;18) ⁻ negative follicular lymphoma support a late germinal center B-cell phenotype. <i>Blood</i> , 2011, 118, 5550-5558.	0.6	77
74	CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 ⁺ mantle cell lymphoma. <i>Blood</i> , 2019, 133, 940-951.	0.6	77
75	Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. <i>Blood</i> , 2001, 97, 1845-1853.	0.6	75
76	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. <i>Blood</i> , 2012, 119, 3757-3766.	0.6	72
77	The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>American Journal of Clinical Pathology</i> , 2011, 135, 54-61.	0.4	71
78	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. <i>Blood</i> , 2017, 129, 759-770.	0.6	69
79	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. <i>Blood</i> , 2005, 107, 1101-1107.	0.6	68
80	Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues. <i>Clinical Cancer Research</i> , 2011, 17, 3727-3732.	3.2	68
81	T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. <i>Haematologica</i> , 2010, 95, 440-448.	1.7	66
82	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	0.6	64
83	Primary low-grade B-cell lymphoma of MALT-type occurring in the liver: a study of two cases. <i>Journal of Hepatology</i> , 1997, 27, 922-927.	1.8	63
84	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1322-1330.	2.1	63
85	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. <i>Blood</i> , 2017, 130, 1819-1831.	0.6	62
86	Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organs. <i>BMC Immunology</i> , 2004, 5, 20.	0.9	59
87	Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. <i>Blood</i> , 2010, 116, 1489-1497.	0.6	58
88	Related F-box proteins control cell death in <i>Caenorhabditis elegans</i> and human lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3943-3948.	3.3	57
89	The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2016, 175, 102-114.	1.2	56
90	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and Tj ETQq0 0 0 rBT/Overlock 10 Tf 428-435.	2.0	56

#	ARTICLE	IF	CITATIONS
91	Lymphomatous Polyposis. <i>American Journal of Surgical Pathology</i> , 1996, 20, 442-452.	2.1	54
92	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2290-2296.	0.6	53
93	Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 693-701.	0.6	51
94	Some desmoid tumors are characterized by trisomy 8. <i>Genes Chromosomes and Cancer</i> , 1994, 10, 131-135.	1.5	49
95	Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization. <i>Oncogene</i> , 2005, 24, 1159-1173.	2.6	49
96	NOTCH2 mutations in marginal zone lymphoma. <i>Haematologica</i> , 2008, 93, 1107-1109.	1.7	49
97	Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. <i>Blood</i> , 2014, 123, 1051-1054.	0.6	49
98	Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity. <i>Blood</i> , 2011, 118, 3331-3339.	0.6	47
99	Clinical and Histopathological Features of Folliculotropic Mycosis Fungoides: A Norwegian Patient Series. <i>Acta Dermato-Venereologica</i> , 2013, 93, 325-329.	0.6	46
100	Constitutive Expression of the AP-1 Transcription Factors c-jun, junD, junB, and c-fos and the Marginal Zone B-Cell Transcription Factor Notch2 in Splenic Marginal Zone Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2004, 6, 297-307.	1.2	45
101	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> , 2015, 125, 82-89.	0.6	45
102	How Reliable is Histologic Examination of Bone Marrow Trepine Biopsy Specimens for the Staging of Non-Hodgkin Lymphoma?: A Study of Hairy Cell Leukemia and Mantle Cell Lymphoma Involvement of the Bone Marrow Trepine Specimen by Histologic, Immunohistochemical, and Polymerase Chain Reaction Techniques. <i>American Journal of Clinical Pathology</i> , 1999, 111, 179-184.	0.4	44
103	High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. <i>British Journal of Haematology</i> , 2011, 152, 600-610.	1.2	44
104	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. <i>Blood</i> , 2015, 125, 2669-2677.	0.6	44
105	Splenic Marginal Zone Lymphoma with Villous Lymphocytes Shows On-Going Immunoglobulin Gene Mutations. <i>American Journal of Pathology</i> , 2003, 162, 681-689.	1.9	39
106	Peripheral T-cell lymphoma with involvement of the expanded mantle zone. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 78-87.	1.4	37
107	Distribution of mRNA coding for Alpha-2-macroglobulin, the murinoglobulins, the Alpha-2-macroglobulin receptor and the Alpha-2-macroglobulin receptor associated protein during mouse embryogenesis and in adult tissues. <i>Differentiation</i> , 1994, 55, 213-223.	1.0	36
108	Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes. <i>British Journal of Haematology</i> , 1998, 102, 1301-1306.	1.2	36

#	ARTICLE	IF	CITATIONS
109	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1090-1097.	1.5	36
110	Characterization of a novel immunoglobulin-like domain containing receptor. <i>Biochemical and Biophysical Research Communications</i> , 2004, 323, 970-978.	1.0	35
111	The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. <i>Journal of Pathology</i> , 2006, 208, 431-438.	2.1	35
112	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 2144-2153.	1.1	34
113	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow. <i>American Journal of Clinical Pathology</i> , 2015, 143, 797-806.	0.4	31
114	Concurrent Lymphocyte Predominance Hodgkin's Disease and T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 1996, 20, 355-362.	2.1	30
115	Distribution of non-lymphoid, inflammatory cells in chronic HBV infection. <i>Journal of Pathology</i> , 1990, 160, 223-230.	2.1	29
116	Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 139, 242-254.	0.4	29
117	Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma. <i>Epigenetics</i> , 2014, 9, 428-436.	1.3	29
118	G-banding and molecular cytogenetic analyses of marginal zone lymphoma. <i>British Journal of Haematology</i> , 2005, 130, 890-901.	1.2	28
119	New probabilistic graphical models for genetic regulatory networks studies. <i>Journal of Biomedical Informatics</i> , 2005, 38, 443-455.	2.5	27
120	MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, 654.	2.8	26
121	CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma. <i>ISRN Oncology</i> , 2013, 2013, 1-4.	2.1	25
122	Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. <i>Blood Advances</i> , 2020, 4, 993-996.	2.5	25
123	T-cell lymphoma developing in Hodgkin's disease: Evidence for two clones. <i>Journal of Pathology</i> , 1993, 170, 239-248.	2.1	24
124	Transformation of B cell lymphoma to histiocytic sarcoma: somatic mutations of PAX-5 gene with loss of expression cannot explain transdifferentiation. <i>Journal of Hematopathology</i> , 2009, 2, 135-141.	0.2	24
125	Two courses of four weekly infusions of rituximab with or without interferon- γ 2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 2598-2607.	0.6	24
126	Granulomatous Slack Skin With a Translocation t(3;9)(q12;p24). <i>American Journal of Surgical Pathology</i> , 2007, 31, 803-806.	2.1	23

#	ARTICLE	IF	CITATIONS
127	Comprehensive genome-wide transcription factor analysis reveals that a combination of high affinity and low affinity DNA binding is needed for human gene regulation. <i>BMC Genomics</i> , 2015, 16, S12.	1.2	23
128	Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2017, 102, e195-e198.	1.7	23
129	The Antigen-Presenting Cell Function of Reed-Sternberg Cells. <i>Leukemia and Lymphoma</i> , 1995, 18, 35-40.	0.6	22
130	Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 407-411.	1.4	22
131	Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. <i>PLoS ONE</i> , 2015, 10, e0131158.	1.1	22
132	Bone Marrow Histology in Monoclonal B-Cell Lymphocytosis Shows Various B-Cell Infiltration Patterns. <i>American Journal of Clinical Pathology</i> , 2013, 139, 390-395.	0.4	21
133	Concurrent mediastinal germ-cell tumour and haematological malignancy: Case report and short review of literature. <i>Acta Oncologica</i> , 2008, 47, 466-469.	0.8	20
134	Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e91031.	1.1	19
135	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. <i>Haematologica</i> , 2009, 94, 596-598.	1.7	18
136	Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma. <i>BMC Cancer</i> , 2012, 12, 478.	1.1	18
137	Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma. <i>Scientific Reports</i> , 2017, 7, 7040.	1.6	18
138	CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. <i>Blood Advances</i> , 2018, 2, 3506-3514.	2.5	18
139	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1742-1749.	0.6	17
140	Identification of Highly Methylated Genes across Various Types of B-Cell Non-Hodgkin Lymphoma. <i>PLoS ONE</i> , 2013, 8, e79602.	1.1	16
141	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. <i>International Journal of Cancer</i> , 2013, 133, 2852-2863.	2.3	15
142	Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. <i>British Journal of Haematology</i> , 1999, 106, 1045-1048.	1.2	14
143	Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type. <i>Haematologica</i> , 2010, 95, 1334-1341.	1.7	13
144	A Gene Panel, Including LRP12, Is Frequently Hypermethylated in Major Types of B-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e104249.	1.1	13

#	ARTICLE	IF	CITATIONS
145	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016, 57, 717-720.	0.6	13
146	Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma. <i>Histopathology</i> , 2015, 67, 62-69.	1.6	12
147	Breast implant-associated EBV-positive diffuse large B-cell lymphoma: Two case reports and literature review. <i>Pathology Research and Practice</i> , 2021, 226, 153589.	1.0	12
148	PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promoter. <i>Journal of Pathology</i> , 2005, 206, 312-319.	2.1	11
149	Gene Expression Signatures Predict Overall Survival in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy. <i>Blood</i> , 2007, 110, 348-348.	0.6	11
150	Intensifying Methotrexate (MTX) Dosage Reduces Treatment Failure in Adults with Burkitt or Burkitt-Like Leukaemia/Lymphoma (BL) Treated with an Adapted BFM Protocol. <i>Blood</i> , 2006, 108, 2438-2438.	0.6	11
151	Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. <i>European Journal of Haematology</i> , 2013, 91, 332-338.	1.1	10
152	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. <i>Blood</i> , 2014, 124, 3016-3016.	0.6	10
153	Molecular Cloning of a Gene on Chromosome 19q12 Coding for a Novel Intracellular Protein: Analysis of Expression in Human and Mouse Tissues and in Human Tumor Cells, Particularly Reed-Sternberg Cells in Hodgkin Disease. <i>Genomics</i> , 1998, 54, 511-520.	1.3	9
154	t(14;22)(q32;q11) in non-Hodgkin lymphoma and myeloid leukaemia: molecular cytogenetic investigations. <i>British Journal of Haematology</i> , 2005, 130, 845-851.	1.2	9
155	Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 559-565.	1.4	9
156	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. <i>Leukemia and Lymphoma</i> , 2009, 50, 1875-1878.	0.6	9
157	Restin in Hodgkin's Disease and Anaplastic Large Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1993, 12, 21-26.	0.6	7
158	Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features) Tj ETQq0 0 0 rgBT /Overlock 10	2.0	7
159	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations. <i>Blood</i> , 2007, 110, 360-360.	0.6	7
160	Characterization of the MicroRNA Expression Profiles of Paired Primary and Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) By Next-Generation Sequencing. <i>Blood</i> , 2014, 124, 1626-1626.	0.6	7
161	Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 1119-1126.	2.0	6
162	Molecular cytogenetic analysis of leukemic mantle cell lymphoma with a cryptic t(11;14). <i>Cancer Genetics and Cytogenetics</i> , 2006, 165, 172-175.	1.0	5

#	ARTICLE	IF	CITATIONS
163	Altered <scp>BCR</scp> and <scp>CD</scp>40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients. <i>British Journal of Haematology</i> , 2012, 159, 0-0.	1.2	5
164	Primary Marginal Zone Lymphoma of the Subcutis Associated With Panniculitis and Fat Necrosis. <i>American Journal of Clinical Pathology</i> , 2015, 144, 341-346.	0.4	5
165	Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 623-632.	0.6	5
166	BayesPI-BAR2: A New Python Package for Predicting Functional Non-coding Mutations in Cancer Patient Cohorts. <i>Frontiers in Genetics</i> , 2019, 10, 282.	1.1	5
167	Primary Cutaneous Follicular Helper T-cell Lymphoma in a Patient With Neurofibromatosis Type 1: Case Report and Review of the Literature. <i>American Journal of Dermatopathology</i> , 2017, 39, 134-139.	0.3	5
168	Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01). <i>Blood</i> , 2010, 116, 3566-3566.	0.6	5
169	Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.. <i>Blood</i> , 2007, 110, LB1-LB1.	0.6	5
170	Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab. <i>Blood</i> , 2011, 118, 1641-1641.	0.6	5
171	Cytogenetic characterization of three cases of unusual B-cell non-Hodgkin's lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 1991, 53, 229-235.	1.0	4
172	Hodgkin's Disease: Lineage and Clonality. <i>American Journal of Clinical Pathology</i> , 1995, 104, 368-370.	0.4	4
173	Richter syndrome presenting as a solitary cerebellar tumor during first-line treatment for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 2007-2009.	0.6	4
174	The first report of a previously undescribed EBV-negative NK-cell lymphoma of the GI tract presenting as chronic diarrhoea with eosinophilia. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212103.	0.2	4
175	Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01). <i>Blood</i> , 2010, 116, 3565-3565.	0.6	4
176	Molecular Signatures to Improve Diagnosis, Prognostication and Identification of Oncogenic Pathways in Peripheral T and NK Cell Lymphoma.. <i>Blood</i> , 2008, 112, 3339-3339.	0.6	4
177	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. <i>Blood</i> , 2019, 134, 19-19.	0.6	4
178	Mantle cell lymphoma with features of marginal-zone lymphoma. <i>Journal of Hematopathology</i> , 2011, 4, 7-11.	0.2	3
179	Multiple Distinct T-Cell Clones in Folliculotropic Mycosis Fungoides. <i>American Journal of Dermatopathology</i> , 2014, 36, 972-976.	0.3	3
180	Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell. <i>Haematologica</i> , 2015, 100, e415-e418.	1.7	3

#	ARTICLE	IF	CITATIONS
181	High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01). <i>Blood</i> , 2011, 118, 331-331.	0.6	3
182	Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin. <i>Blood</i> , 2012, 120, 747-747.	0.6	3
183	A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. <i>Blood</i> , 2014, 124, 3094-3094.	0.6	3
184	Binding of rabbit immunoglobulins to melanoma cells: a pitfall in the immunohistochemical study of malignant melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 421-422.	1.4	2
185	Localized lymphoid hyperplasia of the spleen: a rare benign condition grossly mimicking malignancy. <i>Journal of Hematopathology</i> , 2016, 9, 85-89.	0.2	2
186	Folliculotropic Mycosis Fungoides with Skewed T-cell Receptor CDR3 Motif: Suggestive of Lipid-antigen Selection?. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1081-1086.	0.6	2
187	DNA Methylation-Based Classification of Small B-Cell Lymphomas. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1774-1786.	1.2	2
188	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2007, 110, 692-692.	0.6	2
189	R-CHOEP-14 Å— 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2â€™3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18â€™65 Years.. <i>Blood</i> , 2010, 116, 2805-2805.	0.6	2
190	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2012, 120, 679-679.	0.6	2
191	Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM. <i>Blood</i> , 2013, 122, 1768-1768.	0.6	2
192	Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH.. <i>Blood</i> , 2007, 110, 2631-2631.	0.6	2
193	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2010, 116, 2005-2005.	0.6	2
194	Nuclear segmentation anomalies of neutrophils in neutrophilic dermatosis associated with myelodysplasia syndrome. <i>Journal of the American Academy of Dermatology</i> , 1991, 24, 1037.	0.6	1
195	Malignant Lymphoma of the Tongue with Unusual Cytology in a Pleural Effusion. <i>Acta Cytologica</i> , 2010, 54, 645-648.	0.7	1
196	Prognostic markers in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 1588-1589.	0.6	1
197	Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEACâ€™Autologous stem-cell support: still very long survival but. <i>British Journal of Haematology</i> , 2012, 158, 815-816.	1.2	1
198	Primary Mediastinal Large B-Cell Lymphoma. , 2014, , 195-206.		1

#	ARTICLE	IF	CITATIONS
199	Testicular Diffuse Large B-Cell Lymphoma of Activated B-Cell Subtype Is Frequently Associated with Clonally Related Non-Follicular Small B-Cell Lymphoma in the Bone Marrow.. Blood, 2006, 108, 2042-2042.	0.6	1
200	Alternative Splicing and Expression of Class II Tubulin Beta (TUBB2B) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1557-1557.	0.6	1
201	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. Blood, 2004, 104, 415-415.	0.6	1
202	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. Blood, 2008, 112, 475-475.	0.6	1
203	Principles of the Pathology and Biology of Malignant Lymphomas. , 2014, , 3-16.		1
204	Cold Agglutinin Disease Shows Highly Recurrent Gains of Chromosome 3, 12 and 18. Blood, 2019, 134, 1488-1488.	0.6	1
205	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. Blood, 2021, 138, 1326-1326.	0.6	1
206	Concurrent Primary Follicular Lymphoma and a Mature Cystic Teratoma of the Ovary: A Case Report and Review of Literature. Case Reports in Pathology, 2022, 2022, 1-5.	0.2	1
207	Integrating whole genome sequencing, methylation, gene expression, topologically associated domain information in regulatory mutation prediction: A study of follicular lymphoma. Computational and Structural Biotechnology Journal, 2022, 20, 1726-1742.	1.9	1
208	Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives of Pathology and Laboratory Medicine, 2023, 147, 79-86.	1.2	1
209	Diffuse large B-cell lymphoma cycling off the main track. Leukemia and Lymphoma, 2011, 52, 358-359.	0.6	0
210	Keeping good and bad company: stromal cells in lymphoma. Leukemia and Lymphoma, 2012, 53, 1654-1655.	0.6	0
211	Malignant Phylloides Tumor and Acute Megakaryoblastic Leukemia Sharing a Common Clonal Origin. Case Reports in Hematology, 2013, 2013, 1-4.	0.3	0
212	Personalized lymphoma diagnosis and treatment: recent advances. Diagnostic Histopathology, 2014, 20, 431-439.	0.2	0
213	Non-MALT Marginal Zone Lymphoma. , 2014, , 241-251.		0
214	VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information.. Blood, 2006, 108, 2421-2421.	0.6	0
215	Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study.. Blood, 2006, 108, 811-811.	0.6	0
216	Loss of CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not Explained by Methylation of CIITA Promoters III and IV.. Blood, 2008, 112, 1786-1786.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.. Blood, 2008, 112, 2049-2049.	0.6	0
218	R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2â€™3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years. Blood, 2008, 112, 3604-3604.	0.6	0
219	NK-Cell Lymphoma Shares Strikingly Similar Molecular Features with a Distinct Set of Î³ T-Cell Lymphoma and Identification of Aurora Kinase A Inhibitor as a Novel Therapeutic Agent.. Blood, 2009, 114, 313-313.	0.6	0
220	Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.. Blood, 2009, 114, 620-620.	0.6	0
221	Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL).. Blood, 2009, 114, 2922-2922.	0.6	0
222	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948.	0.6	0
223	Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmunotherapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. Blood, 2010, 116, 3107-3107.	0.6	0
224	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. Blood, 2011, 118, 435-435.	0.6	0
225	Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2012, 30, 8074-8074.	0.8	0
226	Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.. Blood, 2012, 120, 2648-2648.	0.6	0
227	Global Profiling Of Outcome Associated Alternative Splicing Events and Gene Expression In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 75-75.	0.6	0
228	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue â€™ An L.L.M.P.P. Project. Blood, 2013, 122, 73-73.	0.6	0
229	Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort. Blood, 2013, 122, 4272-4272.	0.6	0
230	Primary Cold Agglutinin Associated Lymphoproliferative Disease: A B-Cell Lymphoma Of The Bone Marrow Distinct From Lymphoplasmacytic Lymphoma. Blood, 2013, 122, 4335-4335.	0.6	0
231	Cutaneous T-Cell Lymphoma. , 2014, , 133-167.		0
232	Nodular Lymphocyte-Predominant Hodgkin Lymphoma. , 2014, , 343-352.		0
233	Anaplastic Large Cell Lymphoma. , 2014, , 111-120.		0
234	WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2014, , 303-329.		0

#	ARTICLE	IF	CITATIONS
235	Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma. , 2014, , 253-276.		0
236	Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials. Blood, 2014, 124, 2994-2994.	0.6	0
237	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. Blood, 2014, 124, 1667-1667.	0.6	0
238	Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma. Blood, 2019, 134, 2027-2027.	0.6	0
239	The Mutational Landscape of Cold Agglutinin Disease. Blood, 2020, 136, 14-15.	0.6	0